All articles tagged with #retatrutide
A man on retatrutide, an experimental GLP-1 weight-loss drug from Eli Lilly, posts dramatic before-and-after photos claiming about 85 pounds lost over two years; the drug is still in development and not yet available in the UK, though GLP-1 therapies are used for weight loss in the NHS under certain conditions; the posts emphasize health and longevity over appearance.
Eli Lilly's retatrutide, a weekly triple hormone receptor agonist (GLP-1, GIP, glucagon), produced an average 28.3% weight loss (70.3 lb) over 80 weeks at the 12 mg dose in a Phase 3 trial of 2,339 adults with obesity or overweight and a weight-related comorbidity. The 12 mg group lost more weight than the 9 mg and 4 mg groups, with 65.3% reaching a BMI below 30 and 37.5% starting with BMI ≥40; 45.3% achieved at least 30% weight loss. Retatrutide’s weight loss appears to exceed current drugs Wegovy and Zepbound. The drug, which combines GLP-1 and GIP with glucagon, also improved cardio-metabolic risk factors, though side effects such as nausea, diarrhea, constipation, and vomiting increased with dose.
Lilly’s triple-G obesity drug retatrutide met primary endpoints in Phase 3 TRIUMPH-1, delivering up to 28.3% weight loss at 80 weeks for the highest dose on the efficacy estimand (vs 2.2% for placebo). On the treatment-regimen estimand, weight losses were 17.6% (4 mg), 23.7% (9 mg) and 25% (12 mg) with placebo at 3.9%. A Week 104 readout for the top dose reached 29.9% among patients who stayed on therapy. The topline did not include sleep apnea or osteoarthritis pain data. Safety showed higher discontinuations at the high dose (11.3% vs 4.9% placebo) and notable dysesthesia (20.9% at high dose); GI adverse events were more common at the low dose. Analysts said the results meet key endpoints but didn’t exceed expectations, and Lilly is eyeing possible FDA submission this year amid competition from Wegovy and other obesity drugs.
Eli Lilly announced topline TRIUMPH-1 results for retatrutide, a first-in-class GIP/GLP-1/glucagon triple agonist, in adults with obesity or overweight and comorbidities. Across 4 mg, 9 mg, and 12 mg doses, participants achieved meaningful weight loss at 80 weeks (4 mg: 19.0%, 9 mg: 25.9%, 12 mg: 28.3%), with the 12 mg group averaging 70.3 lb and 45.3% reaching ≥30% weight loss; BMI ≤22 was achieved by 65.3% at Week 80. Some participants with higher BMI continued losing weight in extensions, reaching about 30% total body weight loss over roughly two years. All arms met primary and key secondary endpoints, and the follow-on extension data covered up to 104 weeks. Safety disclosures mirror warnings associated with Lilly's obesity medicines.
In the TRIUMPH-1 Phase 3 trial, Lilly’s triple hormone agonist retatrutide produced clinically meaningful weight loss across all dose groups over 80 weeks: 12 mg yielded an average 70.3 lb loss (28.3%) with 45.3% achieving ≥30% weight reduction, and 65.3% reached BMI 22 at Week 80; 9 mg achieved 64.4 lb (25.9%) and 4 mg 47.2 lb (19.0%). An extension up to 104 weeks showed continued weight loss in some participants, including those with higher baseline BMI. The data support retatrutide’s potential as a non-surgical obesity treatment, with detailed safety labeling included in the release.
Lilly reports that retatrutide, a triple agonist of GLP-1, GIP, and glucagon, produced up to about 85 pounds (roughly 30% of body weight) loss in a phase 3 trial of ~2,300 people with obesity or overweight, with the highest weekly dose averaging 28% weight loss over 80 weeks (some participants continued to 104 weeks). If approved, it could surpass current GLP-1 meds and aid patients who don’t respond to those drugs. Side effects include nausea, GI issues, skin sensations, and UTIs. Full results haven’t been published in a medical journal, and an FDA filing could occur as early as this year.
Phase 3 data show Lilly’s investigational triple-hormone drug retatrutide delivering up to 28.3% average weight loss over 80 weeks at the highest dose (vs. 2.2% placebo), with about 45% of patients achieving 30%+ loss and even greater reductions in those with BMI ≥35. A lower 4 mg dose yielded 19% weight loss with better tolerability. Common side effects were GI (nausea, diarrhea, constipation); no major cardiac or liver issues were observed. If results hold, Lilly could file for approval, potentially solidifying retatrutide as a top player in a booming obesity market, ahead of Novo Nordisk’s competing therapies.
A 32-year-old man developed intractable diarrhea and dehydration after accidentally doubling his weekly dose of retatrutide, an experimental GLP-1/GIP/glucagon agonist bought online. He was hospitalized for four days, recovered, and the case underscores the risks of using non-approved obesity drugs without medical supervision amid a growing black market and strong trial results.
AI analyzed about 70,000 Reddit comments from a pool of ~400,000 posters to identify GLP-1 side effects. Found common issues like nausea, vomiting, and constipation that align with clinical trials, but also signals less frequently reported, such as menstrual irregularities (~4%) and temperature-related symptoms, prompting further validation. Also notes online discussion about the weight-loss drug Retatrutide (tri-agonist) not yet approved.
Retatrutide is an experimental peptide that targets GLP-1, GIP, and glucagon to suppress appetite and boost fat loss; it’s unapproved globally and already circulating online, with early trials showing strong weight loss but under strict medical supervision. Real‑world use carries safety concerns like gastrointestinal side effects and at least one death being investigated; lack of regulation means contaminated or misdosed products are possible, and Australia’s TGA has warned about importing unapproved peptides. Experts caution that achieving shredded results depends on resistance training and protein intake, and mood or relationship effects are still unclear.
Retatrutide is an experimental peptide that may drive substantial weight loss by modulating appetite and metabolism, but it is not approved anywhere, carries gastrointestinal and mood-related risks, and unregulated online access raises safety concerns; achieving a shredded appearance still depends on resistance training and a protein-rich diet under medical supervision.
Lilly reports positive topline results from TRANSCEND-T2D-1, a Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist (GIP, GLP-1, glucagon), showing up to a 2.0% reduction in A1C and about 17% body-weight loss at 40 weeks versus placebo, with dose-dependent effects and continued weight loss through the treatment period. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting) largely during dose escalation, with some dysesthesia but generally manageable. Results met primary and key secondary endpoints and will be detailed at the ADA Scientific Sessions in June; Lilly plans to publish additional data from the retatrutide program over the next year.
Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.
Trial results for Eli Lilly’s retatrutide show about 28.7% weight loss after 68 weeks, higher than current meds, but with 12–18% dropout due to side effects and some participants reporting they were losing too much weight. Health experts caution about malnutrition and disordered eating, advocating dosing that is tailored to the patient and kept at the lowest effective level as obesity becomes a chronic disease; Novo Nordisk’s CagriSema uses flexible dosing to manage safety as full data from the retatrutide trial await publication.
Eli Lilly announced a $3.5 billion manufacturing plant in Pennsylvania’s Lehigh Valley to produce its next-generation obesity therapies, including the experimental drug retatrutide. The new facility, Lilly’s fourth major U.S. site, is slated to start this year and become operational in 2031, creating about 850 local jobs and 2,000 construction roles, as the company seeks to expand capacity amid strong GLP-1 market competition and ongoing push to secure drug supply.